Breaking News, Collaborations & Alliances

Quotient To Perform Development and Testing for MediGene

Will undertake formulation development and clinical testing for RhuDex RA treatment

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Quotient Clinical, a business unit of Quotient Bioresearch, will work with MediGene AG to undertake a RapidFACT formulation development and clinical testing program on MediGene’s RhuDex, subject to ethical and Medicines and Healthcare products Regulatory Agency (MHRA) approval. Rhudex is a new potential first-in-class treatment for rheumatoid arthritis and other inflammatory disorders. Quotient Clinical’s RapidFACT service leverages its integrated GMP manufacturing and clinical testing pr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters